Saihe Medical, Nuowei Bio, and Xuanyan Bio File IPO Prospectuses Following Recent Funding Rounds

Oct 26, 2023 22:28 CST Updated 22:28

SONOSEMI

Active Vascular Implantable and Interventional Medical Device R&D and Manufacturer

VILLANELLE LIFE

AI-Assisted Diagnosis and Drug Platform Developer

SONOSEMI Completes Over 200 Million RMB in Series B Financing

Recently, Sonosemi Medical Co., Ltd. (hereinafter referred to as "SONOSEMI") has completed a B-round financing of over 200 million RMB. This round of financing was jointly led by Yuexiu Industrial Fund and Jianxin Equity, with Cornerstone Capital participating as a follow-up investor. Original shareholders Tencent Investment, Eight Roads Ventures, and Yahui Investment continued to increase their investment, demonstrating the investors' confidence in the company's future development. Dandelion Capital served as the exclusive financial advisor.

The funds raised in this round will be used for the research, development, production, and commercialization of core products. SONOSEMI will continue to focus on the layout and development of products for comprehensive vascular precision diagnosis and treatment solutions, enriching and continuously iterating the company’s product portfolio. At the same time, SONOSEMI has set its sights on the international market, actively pursuing global patents, and advancing overseas registration and clinical plans.

SONOSEMI, founded in April 2020 and headquartered in Shenzhen, has broken through the technical barriers of overseas high-end medical devices in its three years of development. It has independently developed innovative products for泛血管 active intervention, including a coronary intravascular shock wave treatment system, peripheral arterial intravascular shock wave treatment system, intracardiac ultrasound imaging system, and intravascular ultrasound. It is expected that by the end of 2024, the company will form a product matrix consisting of 4-6 products to provide customers with comprehensive, all-around solutions.

SONOSEMI builds an innovative product matrix for precise interventional diagnosis and treatment in coronary, peripheral, structural heart disease, and electrophysiology. Targeting unmet clinical needs and pain points in existing interventional therapies, it simplifies surgical procedures, improves operational efficiency, reduces medical costs, and collaborates with industry partners and supply chain resources to provide patients with greener, safer, more economical, and efficient inclusive solutions.

As of now, SONOSEMI has applied for more than 100 patents of various kinds, including over 50 invention patents. It has maintained a leading technological edge in the field of泛血管有源介入 (pan-vascular active interventional), achieved the localization of pan-vascular active interventional products in China, and filled the domestic industrial gap.

VILLANELLE LIFE Completes 50 Million Pre-B Round Financing

Recently, VILLANELLE LIFE announced the completion of a 50 million yuan Pre-B round of financing. This round of financing was jointly invested by New Investment Jingshi and Focus Fund. The funds will be used to accelerate the clinical research of VILLANELLE LIFE's new anti-tumor nucleic acid drugs developed based on the STARi platform, expand the professional team, and develop a globally pioneering disruptive anti-tumor new drug pipeline.

As a biopharmaceutical innovation company dedicated to the gene therapy field, VILLANELLE LIFE focuses on unmet clinical needs with a unique commercial perspective and continuously advances "China-originated" nucleic acid drug research of the First-in-class type with full independent intellectual property rights. The company’s R&D team is led by Academician Jiang Jiandong and guided by authoritative experts from the CDE of China’s National Medical Products Administration. The core technical leaders include Dr. Liu Defang and Dr. Qi Hailong, two "Science and Technology Rising Stars" of Beijing, from Peking University. The team comprises over 10 high-caliber postdoctoral researchers and Ph.D. talents from prestigious institutions such as Peking University, Tsinghua University, Nankai University, University of Science and Technology of China, Chinese Academy of Sciences, and Chinese Academy of Medical Sciences, as well as experienced industrialization professionals specializing in clinical medicine registration (with master's and doctoral talents accounting for nearly 70%).

The Newway team leverages complementary strengths and efficient collaboration, achieving two Class 1 new drug IND approvals from scratch in the past three years (with a third IND already accepted). They have obtained over 40 invention patents in areas such as cell and gene therapy, nucleic acid drugs, and cancer vaccines. Additionally, they have published six SCI papers as the first or corresponding author institution and received significant special funding support from the Beijing Municipal Science & Technology Commission.

With profound strength and past successful experience, Novelle Biotech has laid out multiple product R&D pipelines. Two core products with relatively rapid progress have entered the clinical research stage this year: the liver cancer therapeutic DNA nucleic acid drug NWRD06 received clinical approval from the CDE of the National Medical Products Administration in May 2023, and the HPV therapeutic DNA nucleic acid drug NWRD08 has completed a 7-case IIT study, demonstrating good safety and leading efficacy data in the industry. The formal clinical trial application (IND) for NWRD08 has been accepted by the CDE and is expected to be approved for clinical development within the year.

VILLANELLE LIFE Completes Multi-Million Yuan Angel Round Financing

Early screening, diagnosis, progression management, and treatment of complex diseases (such as cancer and cardiovascular diseases) have always been difficult challenges in the medical field. With the rise of artificial intelligence, AI has been widely applied in the medical domain, demonstrating significant advantages and potential in assisting healthcare professionals with disease diagnosis, risk assessment, and treatment.

This field has recently witnessed another significant event.VILLANELLE LIFE (Shanghai Villanelle Biotechnology Co., Ltd.) announced the completion of an angel round of financing worth tens of millions of yuan, exclusively led by Hainan Qianganghui Investment Partnership.The funds raised will be used for the preclinical research of INTX-001, a world-first cancer target antibody drug, the development of downstream IVD pipelines, and IVD products and software related to AI prediction of major disease progression (early screening, metastasis, etc.).

VILLANELLE LIFE was founded in April 2021, dedicated to creating an AI-driven drug discovery, early screening, and auxiliary diagnostic platform to address unmet needs. Guided by the principle of precision medicine, the company has developed an AI-based novel drug target mining platform. Leveraging clinical samples from real patients collected from over twenty top-tier tertiary hospitals, combined with exclusive AI algorithms and bioinformatics analysis technologies, the company has established a unique integrated precision medicine platform. This platform spans from upstream target and biomarker discovery to downstream drug development, early screening, and auxiliary diagnostics, aiming to meet the long-standing clinical demands for early screening, diagnosis, progression management, and treatment of complex diseases (such as cancer, acute and critical illnesses, and cardiovascular diseases) that experts have been calling for solutions to for many years.

VILLANELLE LIFE was founded in the United States by Siyu Xiao and Xuanye Cao, alumni of Fudan University's School of Life Sciences, with Professor Dianwen Ju, head of the Department of Biopharmaceuticals at Fudan University's School of Pharmacy, serving as the scientific advisor. The team members are from top universities and institutions both in China and abroad, with 90% holding overseas PhDs, possessing a strong scientific background and work experience in leading medical institutions abroad.

VILLANELLE LIFE's upstream target discovery business has been operating steadily for five years, developing nearly a hundred projects with hospitals and institutions, owning more than ten patents in China and the US, and publishing over twenty academic papers with a combined impact factor exceeding 200. The downstream business has yielded fruitful results, securing global commercialization rights for the monoclonal antibody INTX-001. A patent for the anti-X monoclonal antibody INTX-002 is currently being applied for, with excellent preclinical data showing strong efficacy and safety. The monoclonal antibody drug INTX-001 is expected to file an IND application between 2024-2025 and is anticipated to be approved for marketing by 2028. The monoclonal antibody drug INTX-002 is also expected to file an IND application by mid-2025.

In addition to the drug pipeline, the platform also owns 10 patents for auxiliary diagnostic products, with a rich pipeline layout.

It is reported that VILLANELLE LIFE, utilizing a big data platform and combining cutting-edge algorithms, has successfully constructed several industry-leading models in addition to the previously widely-reported model for predicting severe cases of acute pancreatitis. These include an auxiliary diagnostic model for thyroid cancer metastasis based on expression profiles, as well as a coronary artery stenosis calculation model for coronary heart disease that is precise to the quartile for the first time, among others.

Editor: Zheng Miao

Price War for PCSK9 Lipid-Lowering Drugs Begins! Novartis Challenges the Arena, How Will Innovent, Junshi, and Akeso Respond?

ADC Variable! Partnering with Daiichi Sankyo, Terminating Kelun-Biotech Early Projects — Can Merck's Optimized Portfolio Alleviate the "Blockbuster Drug" Concerns?

500 Designated Retail Pharmacies Inspected! "Purchase, Sales, and Inventory" Data Fully Transparent, Targeting Illegal Use of Medical Insurance Funds

www.yyjjb.com.cn

Insight into Industry Trends

Long press to followPharmaceutical Economy News

"Pharmaceutical Economy News"

Academic Official Account

Focus on the Frontiers of Oncology Academia

Long press to followImmunity Time

"Pharmaceutical Economy News"

Terminal Official Account

Record Major Events in the Pharmaceutical Industry

Long press to follow21st Century Pharmacy